These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33823155)

  • 21. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.
    Fan M; Pfeffer SR; Lynch HT; Cassidy P; Leachman S; Pfeffer LM; Kopelovich L
    Oncotarget; 2013 Jan; 4(1):128-41. PubMed ID: 23371019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
    Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
    Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
    Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
    Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
    Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
    Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
    Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
    J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
    Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
    Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
    Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
    Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
    Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
    Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of germline CDK6 mutations in familial melanoma.
    Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
    Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic carcinoma surveillance in patients with familial melanoma.
    Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
    Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
    Vasen HF; Gruis NA; Frants RR; van Der Velden PA; Hille ET; Bergman W
    Int J Cancer; 2000 Sep; 87(6):809-11. PubMed ID: 10956390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline CDKN2A mutations in childhood melanoma: a case of melanoma-pancreatic cancer syndrome.
    Gironi LC; Colombo E; Farinelli P; Giorgione R; Bozzola C; Ogliara P; Pasini B
    Int J Dermatol; 2015 Dec; 54(12):e553-5. PubMed ID: 26381259
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.
    Ibrahim I; Sibinga Mulder BG; Bonsing B; Morreau H; Farina Sarasqueta A; Inderson A; Luelmo S; Feshtali S; Potjer TP; de Vos Tot Nederveen Cappel W; Wasser M; Vasen HFA
    Eur J Hum Genet; 2018 Aug; 26(8):1227-1229. PubMed ID: 29769629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
    Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
    Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective risk of cancer in CDKN2A germline mutation carriers.
    Goldstein AM; Struewing JP; Fraser MC; Smith MW; Tucker MA
    J Med Genet; 2004 Jun; 41(6):421-4. PubMed ID: 15173226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports.
    van der Wilk BJ; Noordman BJ; Atmodimedjo PN; Dinjens WNM; Laheij RJF; Wagner A; Wijnhoven BPL; van Lanschot JJB
    Eur J Med Genet; 2020 Mar; 63(3):103840. PubMed ID: 31923587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.
    Taylor NJ; Mitra N; Qian L; Avril MF; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Gruis NA; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard AL; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Yang XR; Newton-Bishop JA; Kanetsky PA;
    J Am Acad Dermatol; 2019 Aug; 81(2):386-394. PubMed ID: 30731170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.